128 related articles for article (PubMed ID: 8959644)
1. Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril).
McGuire EJ; Anderson JA; Gough AW; Herman JR; Pegg DG; Theiss JC; de la Iglesia FA
J Toxicol Sci; 1996 Nov; 21(4):207-14. PubMed ID: 8959644
[TBL] [Abstract][Full Text] [Related]
2. Fertility and perinatal/postnatal studies in rats with the angiotensin-converting enzyme inhibitor, quinapril.
Dostal LA; Kim SN; Schardein JL; Anderson JA
Fundam Appl Toxicol; 1991 Nov; 17(4):684-95. PubMed ID: 1778358
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Friehe H; Ney P
Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
[TBL] [Abstract][Full Text] [Related]
4. Renal morphology and function in dogs after treatment with the angiotensin-converting enzyme inhibitor quinapril.
Susick RL; Dominick MA; Ulloa HM; Pegg DG
J Cardiovasc Pharmacol; 1994 Feb; 23(2):275-82. PubMed ID: 7511758
[TBL] [Abstract][Full Text] [Related]
5. Ultrastructural juxtaglomerular cell changes in normotensive rats treated with quinapril, an inhibitor of angiotensin-converting enzyme.
Dominick MA; Bobrowski WF; Metz AL; Gough AW; MacDonald JR
Toxicol Pathol; 1990; 18(3):396-406. PubMed ID: 2267499
[TBL] [Abstract][Full Text] [Related]
6. Renal structure and function in rats after suprapharmacologic doses of quinapril, an angiotensin-converting enzyme inhibitor.
MacDonald JR; Susick RL; Pegg DG; Dominick MA
J Cardiovasc Pharmacol; 1992 Feb; 19(2):282-9. PubMed ID: 1376798
[TBL] [Abstract][Full Text] [Related]
7. Effects of the angiotensin-converting enzyme inhibitor quinapril on renal function in rats.
Graziano MJ; Dethloff LA; Griffin HE; Pegg DG
Arch Int Pharmacodyn Ther; 1993; 324():87-104. PubMed ID: 8297189
[TBL] [Abstract][Full Text] [Related]
8. Quinapril--a preclinical review of the pharmacology, pharmacokinetics, and toxicology.
Kaplan HR; Taylor DG; Olson SC; Andrews LK
Angiology; 1989 Apr; 40(4 Pt 2):335-50. PubMed ID: 2539761
[TBL] [Abstract][Full Text] [Related]
9. Quinapril: overview of preclinical data.
Kaplan HR; Taylor DG; Olson SC
Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII6-12. PubMed ID: 2189623
[TBL] [Abstract][Full Text] [Related]
10. Preclinical safety studies of the combination moexipril hydrochloride/hydrochlorothiazide.
Gietl R; Friehe H; Ney P
Arzneimittelforschung; 1998 Apr; 48(4):365-70. PubMed ID: 9608878
[TBL] [Abstract][Full Text] [Related]
11. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
Larochelle P; Haynes B; Maron N; Dugas S
Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril.
Materson BJ
Am J Cardiol; 1992 Apr; 69(10):46C-53C. PubMed ID: 1546639
[TBL] [Abstract][Full Text] [Related]
13. Pressure overload per se rather than cardiac angiotensin converting enzyme activity may be important in the development of rat cardiac hypertrophy.
Mukawa H; Toki Y; Shimauchi A; Matsui H; Morishima I; Okumura K; Ito T; Hayakawa T
J Hypertens; 1997 Sep; 15(9):1027-32. PubMed ID: 9321751
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
Fabris B; Chen BZ; Pupic V; Perich R; Johnston CI
J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S6-13. PubMed ID: 1691409
[TBL] [Abstract][Full Text] [Related]
15. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats.
Nakajima T; Yamada T; Setoguchi M
J Cardiovasc Pharmacol; 1992 Jan; 19(1):102-7. PubMed ID: 1375675
[TBL] [Abstract][Full Text] [Related]
16. Arterial function in mineralocorticoid-NaCl hypertension: influence of angiotensin-converting enzyme inhibition.
Mäkynen H; Kähönen M; Wu X; Hutri-Kähönen N; Tolvanen JP; Pörsti I
Pharmacol Toxicol; 1997 Oct; 81(4):180-9. PubMed ID: 9353849
[TBL] [Abstract][Full Text] [Related]
17. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
Plosker GL; Sorkin EM
Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
[TBL] [Abstract][Full Text] [Related]
18. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
19. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
[TBL] [Abstract][Full Text] [Related]
20. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
Culy CR; Jarvis B
Drugs; 2002; 62(2):339-85. PubMed ID: 11817979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
